Loss of ADAP1/CentA1 Protects Against Autoimmune Demyelination

Area of Science:

• Neuroimmunology
• Molecular and Cellular Neuroscience
• Autoimmune Diseases

Background:

• ArfGAP with dual PH domain-containing protein 1 (ADAP1), also known as Centaurin alpha-1 (CentA1), is an actin-binding protein primarily found in the CNS.
• ADAP1/CentA1 has known roles in regulating dendritic spine plasticity and has been implicated in Alzheimer's disease, cancer, and HIV reactivation.
• The role of ADAP1/CentA1 in central nervous system (CNS) autoimmunity, particularly in the context of multiple sclerosis (MS), was previously unexplored.

Purpose of the Study:

• To investigate the mechanistic involvement of ADAP1/CentA1 in CNS autoimmunity.
• To determine the impact of ADAP1/CentA1 deficiency on the development and progression of experimental autoimmune encephalomyelitis (EAE), an MS model.
• To elucidate the specific immune cell populations and functions affected by ADAP1/CentA1 in the context of autoimmune responses.

Main Methods:

• Utilized ADAP1/CentA1 deficient mice to model EAE.
• Conducted detailed immunophenotyping to analyze immune cell populations and responses.
• Employed single-cell RNA sequencing (scRNA-seq) to gain high-resolution insights into cellular functions and gene expression profiles.

Main Results:

• ADAP1/CentA1 deficient mice showed partial resistance to EAE development, indicating a role in disease initiation.
• ADAP1/CentA1 was found to be necessary for mounting a sufficient autoimmune response required for EAE initiation and progression.
• ADAP1/CentA1 expression critically impacts the function of regulatory T cells (Tregs), monocytes, and natural killer (NK) cells within the peripheral immune system.

Conclusions:

• ADAP1/CentA1 plays a significant role in the peripheral immune system's response to encephalitogenic challenges, extending its known functions beyond the CNS.
• The study identifies ADAP1/CentA1 as a key regulator in the early molecular events driving CNS autoimmunity.
• Targeting ADAP1/CentA1 function in specific immune cells may offer novel therapeutic strategies for MS and other CNS autoimmune disorders.